Delubac Corporate & Investment Bank supports Biophytis, a biotechnology company (listed on Euronext Growth) specialising in neuromuscular diseases, as advisor and overall coordinator of the capital increase of €3.3 million by private placement with American and European investors.
Biophytis SA is a clinical-stage biotechnology company specialising in the development of drug candidates that slow down degenerative processes and improve functional capacities in patients with age-related diseases, particularly neuromuscular diseases.
Biophytis has successfully completed a capital increase by private placement, totalling 3.3 million euros, subscribed by European and American investors.
Christine Lambert-Goué, Corporate & Investment Bank Director of Banque Delubac & Cie declares: ‘We are very happy to have supported Biophytis in its capital increase. This operation strengthens its equity capital and supplements the financing methods already in place. It has generated strong demand from leading US and European investors. This is a very positive signal and a great sign of confidence for the development prospects of Biophytis.’